x
Filter:
Filters applied
- Coronavirus (COVID-19) Collection
- Zumla, AlimuddinRemove Zumla, Alimuddin filter
- El-Kafrawy, Sherif ARemove El-Kafrawy, Sherif A filter
- 2017 - 2022Remove 2017 - 2022 filter
Author
- Azhar, Esam I3
- Agrati, Chiara2
- Ippolito, Giuseppe2
- Maeurer, Markus2
- Osman, Mohamed2
- Wang, Fu-Sheng2
- Al-Tawfiq, Jaffar A1
- Alam, Intikhab1
- Alandijany, Thamir A1
- Aljohaney, Ahmed1
- AlJohani, Naif I1
- Alshukairi, Abeer N1
- Alsubhi, Tagreed L1
- Bahaudden, Husam A1
- Chang, Chao1
- Cordon-Cardo, Carlos1
- Dada, Ashraf1
- Galle, Peter R1
- Gojobori, Takashi1
- Gorman, Ellen1
- Hassan, Ahmed M1
- Ligeiro, Dário1
- Locatelli, Franco1
Coronavirus (COVID-19) Collection
3 Results
- Case ReportOpen Access
Re-infection with a different SARS-CoV-2 clade and prolonged viral shedding in a hematopoietic stem cell transplantation patient
International Journal of Infectious DiseasesVol. 110p267–271Published online: July 18, 2021- Abeer N. Alshukairi
- Sherif A. El-Kafrawy
- Ashraf Dada
- Muhammad Yasir
- Amani H. Yamani
- Mohammed F. Saeedi
- and others
Cited in Scopus: 8The coronavirus disease 2019 (COVID-19) pandemic continues to spread worldwide (WHO 2020). Understanding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding, transmission dynamics, and re-infection with different SARS-CoV-2 clades in immunocompromised persons is an important clinical and public health challenge (Choi et al., 2020). - Short CommunicationOpen Access
Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants
International Journal of Infectious DiseasesVol. 98p454–459Published online: July 18, 2020- Eric de Sousa
- Dário Ligeiro
- Joana R. Lérias
- Chao Zhang
- Chiara Agrati
- Mohamed Osman
- and others
Cited in Scopus: 35Genetic factors such as the HLA type of patients may play a role in regard to disease severity and clinical outcome of patients with COVID-19. Taking the data deposited in the GISAID database, we made predictions using the IEDB analysis resource (TepiTool) to gauge how variants in the SARS-CoV-2 genome may change peptide binding to the most frequent MHC-class I and -II alleles in Africa, Asia and Europe. We caracterized how a single mutation in the wildtype sequence of of SARS-CoV-2 could influence the peptide binding of SARS-CoV-2 variants to MHC class II, but not to MHC class I alleles. - EditorialOpen Access
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies
International Journal of Infectious DiseasesVol. 96p431–439Published online: May 17, 2020- Alimuddin Zumla
- Fu-Sheng Wang
- Giuseppe Ippolito
- Nicola Petrosillo
- Chiara Agrati
- Esam I. Azhar
- Chao Chang
- Sherif A. El-Kafrawy
- Mohamed Osman
- Laurence Zitvogel
- Peter R. Galle
- Franco Locatelli
- Ellen Gorman
- Carlos Cordon-Cardo
- Cecilia O’Kane
- Danny McAuley
- Markus Maeurer
Cited in Scopus: 36As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations.